Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience

References

• Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood 1998;92:76–82.
   PubMed Web of Science ®Google Scholar
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's Lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124–4130.
   PubMed Web of Science ®Google Scholar
• Mourad N, Mounier N, Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2008;111:4463–4470.
   PubMed Web of Science ®Google Scholar
• Glauco F, Edgar MM, Henry R. Angio-immunoblastic lymphadenopathy: diagnosis and clinical course. Am J Med 1975;59:803–818.
   PubMed Web of Science ®Google Scholar
• Martel P, Laroche L, Courville P, et al. Cutaneous involvement in patients with angioimmunoblastic lymphadenopathy with dysproteinemia: a clinical, immunohistological, and molecular analysis. Arch Dermatol 2000;136:881–886.
   PubMed Web of Science ®Google Scholar
• Bradley SL, Dines DE, Banks PM, Hill RW. The lung in immunoblastic lymphadenopathy. Chest 1981;80:312–318.
   PubMed Web of Science ®Google Scholar
• Cho Y-U, Chi H-S, Park C-J, Jang S, Seo E-J, Huh J. Distinct features of angioimmunoblastic T-cell lymphoma with bone marrow involvement. Am J Clin Pathol 2009;131:640–646.
   PubMed Web of Science ®Google Scholar
• Oka K, Nagayama R, Yatabe Y, Iijima S, Mori N. Angioimmunoblastic T-cell lymphoma with autoimmune thrombocytopenia: a report of two cases. Pathol Res Pract 2010;206:270–275.
   PubMed Web of Science ®Google Scholar
• Notas G, Xylouri I, Kritikos H, Stavroulaki E, Roditakis G, Boumpas D. A rare case of angioimmunoblastic T-cell lymphoma presenting with fever and late polyarthritis. Rheumatology 2009;48:859–860.
   PubMed Web of Science ®Google Scholar
• Siegert W, Nerl C, Agthe A, et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol 1995;6:659–664.
   PubMed Web of Science ®Google Scholar
• Aozasa K, Ohsawa M, Fujita MQ, et al. Angioimmunoblastic lymphadenopathy. Review of 44 patients with emphasis on prognostic behavior. Cancer 1989;63:1625–1629.
   PubMed Web of Science ®Google Scholar
• Chen W-L, Tsai W-C, Chao T-Y, et al. The clinicopathological analysis of 303 cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan. Ann Hematol 2010;89:553–562.
   PubMed Web of Science ®Google Scholar
• Anderson JR, Armitage JO, Weisenburger DD; Non-Hodgkin's Lymphoma Classification Project. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Ann Oncol 1998;9:717–720.
   PubMed Web of Science ®Google Scholar
• Kadin ME, Berard CW, Nanba K, Wakasa H. Lymphoproliferative diseases in Japan and Western countries: proceedings of the United States–Japan seminar, September 6 and 7, 1982, in Seattle, Washington. Hum Pathol 1983;14:745–772.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163–170.
   PubMedGoogle Scholar
• Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474–2479.
   PubMed Web of Science ®Google Scholar
• Maegawa ROB, Hussain S, Danila DC, Teruya-Feldstein J, Maki RG, O'Connor OA. Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings. Leuk Lymphoma 2007;48:2071–2074.
   PubMed Web of Science ®Google Scholar
• de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 2010;148:673–689.
   PubMed Web of Science ®Google Scholar
• Au W-Y, Ma S-Y, Chim C-S, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 2005;16:206–214.
   PubMed Web of Science ®Google Scholar
• Pangalis GA, Moran EM, Nathwani BN, Zelman RJ, Kim H, Rappaport H. Angioimmunoblastic lymphadenopathy long-term follow-up study. Cancer 1983;52:318–321.
   PubMed Web of Science ®Google Scholar
• Archimbaud E, Coiffier B, Bryon PA, Vasselon C, Brizard CP, Viala JJ. Prognostic factors in angioimmunoblastic lymphadenopathy. Cancer 1987;59:208–212.
   PubMed Web of Science ®Google Scholar
• Lee S-S, Rüdiger T, Odenwald T, Roth S, Starostik P, Müller-Hermelink HK. Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4. Int J Cancer 2003;103:12–20.
   PubMed Web of Science ®Google Scholar
• Lee Y, Lee K-W, Kim J-H, et al. Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma. Korean J Intern Med 2008;23:30–36.
   PubMedGoogle Scholar
• Advani R, Horwitz S, Zelenetz A, Horning SJ. Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma 2007;48:521–525.
   PubMed Web of Science ®Google Scholar
• Advani R, Warnke R, Sikic BI, Horning S. Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. Ann Oncol 1997;8:601–603.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Wilson WH. Angioimmunoblastic T-cell lymphoma: immune modulation as a therapeutic strategy. Leuk Lymphoma 2007;48:449–451.
   PubMed Web of Science ®Google Scholar
• Ong S, Koeppen H, Larson R, Olopade O. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine. Blood 1996;88:2354–2355.
   PubMed Web of Science ®Google Scholar
• Aguiar Bujanda D. Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. Ann Oncol 2008;19:396–397.
   PubMed Web of Science ®Google Scholar
• Bruns I, Fox F, Reinecke P, et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia 2005;19:1993–1995.
   PubMed Web of Science ®Google Scholar
• Ramasamy K, Lim Z, Pagliuca A, Salisbury JR, Mufti G, Devereux S. et al. Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone. Haematologica 2006;91(Suppl.):ECR44.
   PubMedGoogle Scholar
• Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007;110:2316–2323.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Blood Blood; 2010 Jul 21. [Epub ahead of print].
   Google Scholar
• Schetelig J, Fetscher S, Reichle A, et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 2003;88:1272–1278.
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Canals C, Goldstone A, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome–Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:218–224.
   PubMed Web of Science ®Google Scholar
• Numata A, Miyamoto T, Ohno Y, et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant 2010;45:311–316.
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Canals C, Finke J, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2009;27:3951–3958.
   PubMed Web of Science ®Google Scholar